Alpha Teknova

Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Teknova reports mixed Q4 results, focuses on cost optimization

Teknova's Q4 2022 earnings call highlighted a mixed financial performance with revenue decline offset by full-year growth, emphasizing the importance of strategic investments and operational efficiency.
Challenges in profitability, including a net loss and negative adjusted EBITDA, underscore the need for cost management and revenue optimization strategies to drive sustainable growth.
Despite facing financial hurdles, Teknova's focus on balancing cost reduction with growth initiatives and maintaining liquidity sets the stage for future financial resilience and market competitiveness.

Teknova reports mixed Q1 2023 results, eyes growth opportunities

Teknova's Q1 2023 performance showed a mix of positive and negative indicators, with revenue growth and expense management as strengths, while challenges include declining total revenue and negative adjusted EBITDA. The company's focus on innovation, cost control, and market research presents opportunities for future growth and margin improvement.

TEKNOVA reports robust Q2 revenue growth amidst operational optimizations

TEKNOVA's Q2 2023 showed strong revenue growth and operational improvements.
Despite challenges, the company remains optimistic about its future growth prospects.
Strategic investments in R&D and manufacturing capabilities position TEKNOVA for long-term success.
Efforts to manage expenses and achieve free cash flow targets are key priorities.

Alpha Teknova reports Q3 revenue decline, focuses on financial stability

Alpha Teknova (TKNO) faced revenue declines in Q3 2023, with a net loss of $10.2 million and negative adjusted EBITDA of $5.5 million.
Despite challenges, the company strengthened its financial position through a direct offering, debt repayment, and cost reduction initiatives.
Teknova's focus on managing costs, cash outflows, and strategic investments underscores its commitment to financial stability and operational efficiency.
While facing performance headwinds, Teknova aims to navigate challenges and leverage opportunities for sustainable growth and improved profitability.

Teknova maintains stability, eyes growth through cost savings and partnerships

Teknova's Q4 2023 performance showed stability in revenue and operational improvements, with a focus on cost-saving initiatives and revenue guidance for 2024.
Despite challenges in Clinical Solutions and margin pressures, Teknova's strong customer service, cost reductions, and market opportunities position it for growth.
Strategic partnerships, industry-leading Net Promoter Scores, and a positive outlook on cell and gene therapy approvals present avenues for revenue enhancement and market expansion.

Alpha Teknova (TKNO) reports solid Q1 performance amidst profitability challenges

Alpha Teknova (TKNO) delivered a strong performance in Q1 2024, showcasing revenue growth, cost management success, and operational highlights.
While facing challenges with negative adjusted EBITDA and maintaining gross margin, Teknova's strengths lie in expense management, innovation, and market positioning.
Opportunities for Teknova include product launches, market stabilization, and customer base expansion, setting the stage for future growth and success.
To sustain growth, Teknova must address profitability challenges, balance expense management with revenue growth, and capitalize on market opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2022 Results Conference Call March 15, 2023 5:00 PM ET Company Participants Jen Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Joseph Flanagan - Cowen Matt Larew - William Blair Hannah Hefley - Stephens Operator Thank you for standing by, and welcome to Teknova's Fourth Quarter and Full Year 2022 Financial Results Call. At this time, all participants are in a listen-only mode.

Alpha Teknova, Inc. (TKNO) Q4 2022 Earnings Call Transcript

Full year 2022 total revenue was $41.4 million, up 12% year-over-year New, state-of-the-art manufacturing facility now operational Company provides 2023 revenue guidance of $42-46 million

Teknova Reports Fourth Quarter and Full Year 2022 Financial Results

An AAV chromatography platform plus optimized custom buffer formulations yields a state-of-the-art offering for increased AAV recovery An AAV chromatography platform plus optimized custom buffer formulations yields a state-of-the-art offering for increased AAV recovery

Teknova and Sartorius BIA Separations Announce Collaboration to Address Critical Pain Point in Gene Therapy Process Development

AdaptHealth Corp

Cara Therapeutics

Infinity Pharma

OptimizeRx Corp

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

HOLLISTER, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conferences:

Teknova to Participate in Upcoming Investor Conferences

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q3 2022 Earnings Conference Call November 21, 2022 4:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Teknova Third Quarter 2022 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) Q3 2022 Earnings Call Transcript

Third quarter 2022 total revenue was $10.7 million, up 14% year-over-year Company updates 2022 revenue outlook to $40-42 million Cash position of $50 million supports path to profitability

Teknova Reports Third Quarter 2022 Financial Results

HOLLISTER, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2022, on Wednesday, November 9, 2022, following the close of market.

Teknova to Report Third Quarter 2022 Financial Results on November 9, 2022

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Sara Michelmore - Head of Investor Relations, MacDougall Advisors Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Stephanie Yan - Cowen Matt Larew - William Blair Jake Johnson - Stephens Operator Good day, and thank you for standing by. Welcome to the Teknova Second Quarter 2022 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) CEO Stephen Gunstream on Q2 2022 Results - Earnings Call Transcript

Second quarter 2022 total revenue was $11.7 million, up 41% year-over-year Cash position of $64.7 million supports ongoing investment in growth strategy Company updates 2022 revenue outlook to $38-42 million

Teknova Reports Second Quarter 2022 Financial Results

HOLLISTER, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2022, on Wednesday, August 10, 2022, following the close of market.

Teknova to Report Second Quarter 2022 Financial Results on August 10, 2022

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Sara Michelmore - Head of Investor Relations, MacDougall Advisors Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Matthew Larew - William Blair Stephanie Yan - Cowen and Company Jacob Johnson - Stephens, Inc. Operator Good day, and thank you for standing by. Welcome to the Teknova First Quarter 2022 Financial Results Conference Call.

Alpha Teknova, Inc. (TKNO) CEO Stephen Gunstream on Q1 2022 Results - Earnings Call Transcript

First quarter 2022 total revenue was $11.1 million, up 23% year-over-year Excluding Sample Transport revenue, first quarter 2022 total revenue was $11.1 million, up 37% year-over-year Strong cash position of $76.5 million supports investment in growth strategy

Teknova Reports First Quarter 2022 Financial Results

HOLLISTER, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2022, on Wednesday, May 11, 2022, following the close of market.

Teknova to Report First Quarter 2022 Financial Results on May 11, 2022

Alpha Teknova's (TKNO) CEO Stephen Gunstream on Q4 2021 Results - Earnings Call Transcript

Full year 2021 total revenue was $36.9 million, up 18% year-over-year Excluding Sample Transport revenue of $1.5 million, full year 2021 total revenue was $35.4 million, up 31% year-over-year Company provides 2022 revenue guidance of $44-$48 million

Teknova Reports Fourth Quarter and Full Year 2021 Financial Results

HOLLISTER, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year 2021 on Tuesday, March 15, 2022, following the close of market.

Teknova to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

Company to participate in two upcoming investor conferences in March 2022 Company to participate in two upcoming investor conferences in March 2022

Teknova Announces Preliminary Revenue of $10.0 to $10.1 Million for the Fourth Quarter 2021

HOLLISTER, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will join the Nasdaq Biotechnology Index® (Nasdaq: NBI) effective prior to market open on Monday, December 20, 2021.

Teknova to Join the Nasdaq Biotechnology Index

Alpha Teknova, Inc. (TKNO) CEO Stephen Gunstream on Q3 2021 Results - Earnings Call Transcript

$9.4 million in total revenue, up 5% year-over-year Excluding Sample Transport, total revenue was $9.3 million, up 26% year-over-year Strong cash position of $98.0 million supports investment in long-term growth strategy

Teknova Reports Third Quarter 2021 Financial Results

HOLLISTER, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will report its financial results for the third quarter of 2021 on Wednesday, November 10, 2021, following the close of market.

Teknova to Report Third Quarter 2021 Financial Results on November 10, 2021

—$8.3 million in total revenue, up 38% year-over-year—

Teknova Reports Second Quarter 2021 Financial Results

HOLLISTER, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that on June 29, 2021, it closed its previously announced initial public offering of 6,900,000 shares of its common stock, at a price to the public of $16.00 per share. The closing included 900,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock in the offering. All of the shares of common stock were offered and sold by Teknova.

Teknova Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Elevation Oncology

GH Research PLC

Graphite Bio

Mister Car Wash

Acurx Pharmaceuticals LLC

Missfresh Ltd

Acurx Pharmaceuticals, Alpha Teknova, Elevation Oncology, GH Research, Graphite Bio, and MissFresh are listed on the Nasdaq. Mister Car Wash is trading the New York Stock Exchange.

News for Alpha Teknova Stock (TKNO)